Last checked at 
LONDON (Alliance News) - Biopharmaceutical firm PureTech Health PLC on Wednesday said affiliate Akili Interactive has successfully completed a funding round worth USD55.0 million.
The cash will be used to fund Akili's pipeline of prescription digital treatment candidates, specifically in multiple sclerosis and depression, including proposed ADHD treatment AKL-T01.
PureTech's Chief of Business & Strategy Bharatt Chowrira said: "We are delighted to announce this important financing for Akili, which enables the progression of the pipeline, including AKL-T01, towards commercialisation. Akili is currently preparing to file AKL-T01 for clearance from the US FDA, potentially becoming the first prescription digital treatment for paediatric ADHD."
"Akili has the potential to redefine and improve treatment options for patients living with devastating neurological and psychological conditions, and we look forward to the upcoming readouts across its robust pipeline of candidates."
PureTech shares were up 3.3% on Wednesday at 148.75 pence each.
